Previous FTD biomarker discovery studies using unbiased mass spectrometry (MS)-based technologies identified multiple biomarker candidates (e.g., YKL-40 in FTD and NPTXR in GRN mutation carriers) [30, 31]. The gene discussed is NPTXR; the disease is frontotemporal dementia.